keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis quality of life

keyword
https://www.readbyqxmd.com/read/29037523/a-systematic-review-of-measurement-properties-of-patient-reported-outcome-measures-in-psoriatic-arthritis-a-grappa-omeract-initiative
#1
REVIEW
Pil Højgaard, Louise Klokker, Ana-Maria Orbai, Kim Holmsted, Else M Bartels, Ying Ying Leung, Niti Goel, Maarten de Wit, Dafna D Gladman, Philip Mease, Lene Dreyer, Lars E Kristensen, Oliver FitzGerald, William Tillett, Laure Gossec, Philip Helliwell, Vibeke Strand, Alexis Ogdie, Caroline B Terwee, Robin Christensen
BACKGROUND: An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized controlled trials (RCTs) was endorsed at the Outcome Measures in Rheumatology (OMERACT) meeting in 2016. OBJECTIVES: To synthesize the evidence on measurement properties of patient reported outcome measures (PROMs) for PsA and thereby contribute to development of a PsA core outcome measurement set (COMS) as described by the OMERACT Filter 2.0. METHODS: A systematic literature search was performed in EMBASE, MEDLINE and PsycINFO on Jan 1, 2017 to identify full-text articles with an aim of assessing the measurement properties of PROMs in PsA...
September 9, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29036249/cost-effectiveness-analysis-of-ixekizumab-vs-etanercept-and-their-manufacturer-recommended-dosing-regimens-in-moderate-to-severe-plaque-psoriasis
#2
Jeremy Udkoff, Lawrence F Eichenfield
INTRODUCTION: Biologic therapies have revolutionized the treatment of psoriasis; however, their use is limited by costs. Ixekizumab was more effective than etanercept in the UNCOVER trials, and the Food and Drug Administration (FDA) approved ixekizumab for treating psoriasis. Evaluating the cost-effectiveness of these therapies is crucial for medical decision making and our objective was to determine the cost-effectiveness of various ixekizumab dosing frequencies compared with etanercept...
October 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29031638/dbgaps-a-comprehensive-database-of-genes-and-genetic-markers-associated-with-psoriasis-and-its-subtypes
#3
Shweta Aggarwal, Arnab Nayek, Dibyabhaba Pradhan, Rashi Verma, Monika Yadav, Kalaiarasan Ponnusamy, Arun Kumar Jain
Psoriasis is a systemic hyperproliferative inflammatory skin disorder, although rarely fatal but significantly reduces quality of life. Understanding the full genetic component of the disease association may provide insight into biological pathways as well as targets and biomarkers for diagnosis, prognosis and therapy. Studies related to psoriasis associated genes and genetic markers are scattered and not easily amendable to data-mining. To alleviate difficulties, we have developed dbGAPs an integrated knowledgebase representing a gateway to psoriasis associated genomic data...
October 11, 2017: Genomics
https://www.readbyqxmd.com/read/28979867/body-image-self-esteem-and-quality-of-life-in-patients-with-psoriasis
#4
Hulya Nazik, Selcuk Nazik, Feride C Gul
BACKGROUND: Psoriasis is a chronic inflammatory disease of the skin that may affect the visible areas of body. Hence, the quality of life, self-esteem, and body image can be affected in psoriasis patients. OBJECTIVES: We aimed in the present study to assess the effects of psoriasis on the quality of life, self-esteem, and body image. MATERIALS AND METHODS: The study included 92 patients with psoriasis, along with 98 control participants. The sociodemographic characteristics of the patients were assessed, their Psoriasis Area Severity Index (PASI) scores were calculated to determine the clinical severity of the psoriasis, and the values were recorded...
September 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/28979865/a-prospective-study-of-clinical-profile-in-patients-of-palmoplantar-dermatoses
#5
Pragya A Nair, Nilofar G Diwan, Rochit Singhal, Rita V Vora
BACKGROUND: Palms and soles are the readily visible areas of the body that are affected in various dermatoses. This may have considerable concern to the patient and can cause diagnostic dilemma. Moreover, palmoplantar dermatoses also limit our day to day activities with a significant impact on quality of life. AIM: To study the clinical profile of patients suffering from palmoplantar dermatoses at a tertiary care centre. PATIENTS AND METHODS: A prospective observational study was carried out from June 2014 to May 2015 in the Department of Dermatology, Venerology and Leprosy at a rural tertiary care centre after taking approval from the institutional ethical committee...
September 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/28976906/implementation-of-instrument-based-on-eight-health-related-quality-of-life-domains-for-measuring-of-willingness-to-pay-for-psoriasis-treatment
#6
Hristo P Dobrev, Nikolay G Atanasov, Donka D Dimitrova
BACKGROUND: Psoriasis vulgaris (PsV) is a chronic skin condition that has a major impact on health-related quality of life (HRQOL). AIM: To determine the individual burden of PsV on HRQOL using willingness to pay (WTP) instrument. MATERIALS AND METHODS: Fifty-one consecutive PsV patients were asked to evaluate their overall health and psoriasis affected health by visual analogue scale (VAS), and interviewed on 8 domains (physical, emotional, sleep, work, social, self-care, intimacy, and concentration) of HRQOL and WTP for a hypothetical cure in each domain...
September 1, 2017: Folia Medica
https://www.readbyqxmd.com/read/28976302/certolizumab-pegol-and-secukinumab-for-treating-active-psoriatic-arthritis-following-inadequate-response-to-disease-modifying-antirheumatic-drugs-a-systematic-review-and-economic-evaluation
#7
Mark Corbett, Fadi Chehadah, Mousumi Biswas, Thirimon Moe-Byrne, Stephen Palmer, Marta Soares, Matthew Walton, Melissa Harden, Pauline Ho, Nerys Woolacott, Laura Bojke
BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA(®), Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Secukinumab (SEC; COSENTYX(®), Novartis International AG, Basel, Switzerland) and certolizumab pegol (CZP; CIMZIA(®), UCB Pharma, Brussels, Belgium) have not previously been appraised by NICE...
October 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28969252/association-of-metabolic-syndrome-in-chronic-plaque-psoriasis-patients-and-their-correlation-with-disease-severity-duration-and-age-a-case-control-study-from-western-maharashtra
#8
Aarti Sudam Salunke, Mahendra Vinayak Nagargoje, Vasudha Abhijit Belgaumkar, Sunil Narayan Tolat, Ravindranath Brahmadev Chavan
INTRODUCTION: Psoriasis is a chronic systemic inflammatory disease where the skin and the joints are the primary targets. Despite the fact that psoriasis carries minimal risk of mortality, it is associated with significant morbidity which may have a significant impact on quality of life of patients. Globally, psoriasis has been reported to be associated with Metabolic Syndrome (MS) including obesity, dyslipidemia, diabetes and hypertension. Association of MS and its various components with psoriasis has been consistently reported in various studies, but there is a paucity of data on this association from the Indian subcontinent...
August 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28964451/measurement-properties-of-the-psoriasis-symptom-inventory-electronic-daily-diary-in-patients-with-moderate-to-severe-plaque-psoriasis
#9
Hema N Viswanathan, Alex Mutebi, Cassandra E Milmont, Kenneth Gordon, Hilary Wilson, Hao Zhang, Paul A Klekotka, Dennis A Revicki, Matthias Augustin, Gregory Kricorian, Ajay Nirula, Bruce Strober
OBJECTIVES: The Psoriasis Symptom Inventory (PSI) is a patient-reported outcome instrument that measures the severity of psoriasis signs and symptoms. This study evaluated measurement properties of the PSI in patients with moderate to severe plaque psoriasis. METHODS: This secondary analysis used pooled data from a phase 3 brodalumab clinical trial (AMAGINE-1). Outcome measures included the PSI, Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), psoriasis-affected body surface area, 36-item Short-Form Health Survey version 2, and the Dermatology Life Quality Index (DLQI)...
September 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28954093/the-relationship-between-pruritus-and-clinical-variables-in-patients-with-psoriasis
#10
Anil Gulsel Bahali, Nahide Onsun, Ozlem Su, Dilek Biyik Ozkaya, Didem Dizman, Bugce Topukcu, Omer Uysal
Background: Pruritus is the most commonly occurring subjective symptom of dermatological disease. Published data on both prevalence and intensity of pruritus in psoriasis is limited. Objective: In this study we aimed to investigate the prevalence of pruritus and its relation with psoriasis area severity index, body mass index and presence of systemic disease in patients with psoriasis. Methods: We analyzed data of psoriatic patients diagnosed in our psoriasis outpatient clinic between March 2013 and June 2014 collected retrospectively from PSR-TR registration system...
July 2017: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/28945143/cost-effectiveness-analysis-of-secukinumab-for-the-treatment-of-active-psoriatic-arthritis-a-canadian-perspective
#11
Ron Goeree, Sima Chiva-Razavi, Praveen Gunda, Christopher N Graham, LaStella Miles, Efthalia Nikoglou, Steffen M Jugl, Dafna Gladman
OBJECTIVE: The study evaluates the cost-effectiveness of secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, versus currently licensed biologic treatments in patients with active psoriatic arthritis (PsA) from a Canadian healthcare system perspective. METHODS: A decision analytic semi-Markov model evaluated the cost-effectiveness of secukinumab 150mg and 300mg compared to subcutaneous biologics adalimumab, certolizumab pegol, etanercept, golimumab, and ustekinumab and intravenous biologics infliximab and infliximab biosimilar in biologic-naive and biologic-experienced patients over a lifetime horizon...
September 25, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28944965/comparison-of-psoriasis-and-atopic-dermatitis-guidelines-an-argument-for-aggressive-atopic-dermatitis-management
#12
Mary E Lohman, Peter A Lio
The development of effective systemic treatments has revolutionized the treatment of inflammatory skin diseases. The availability of safe new treatments and the understanding of psoriasis as a systemic disease with comorbidities and effects on quality of life have driven the current aggressive treatment paradigm of psoriasis. Historically the morbidity of atopic dermatitis (AD) has been dismissed, given the perception of AD as "just" a rash. Differences in the guidelines for psoriasis and AD management may suggest variations in the current conceptualization of disease severity and effects on quality of life...
September 25, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28924372/il-36%C3%AE-inhibits-differentiation-and-induces-inflammation-of-keratinocyte-via-wnt-signaling-pathway-in-psoriasis
#13
Wenming Wang, Xiaoling Yu, Chao Wu, Hongzhong Jin
Psoriasis is a common inflammatory skin disease characterized by abnormal keratinocyte inflammation and differentiation that has a major impact on patients' quality of life. IL-36γ, a member of IL-36 cytokine family, is highly expressed in psoriasis and plays an important role in inflammation response and differentiation. However, the function of IL-36γ in differentiation and inflammation of keratinocyte in psoriasis has not been clearly identified. Thus, this study aimed to investigate the role of IL-36γ on differentiation and inflammation in HaCaT cells...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28921458/pharmacogenetics-and-pharmacogenomics-in-moderate-to-severe-psoriasis
#14
REVIEW
María C Ovejero-Benito, Ester Muñoz-Aceituno, Alejandra Reolid, Miriam Saiz-Rodríguez, Francisco Abad-Santos, Esteban Daudén
Pharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis...
September 18, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28919705/new-insight-into-the-pathogenesis-of-nail-psoriasis-and-overview-of-treatment-strategies
#15
REVIEW
Alessandra Ventura, Mauro Mazzeo, Roberta Gaziano, Marco Galluzzo, Luca Bianchi, Elena Campione
Psoriasis is a chronic inflammatory disease affecting up to 3% of the general population. The prevalence of nail involvement in psoriasis patients varies between 15% and 79%. While the nails represent a small portion of the body surface area, psoriasis in these areas can have a disproportionate influence on a patient's physical and psychosocial activities. Differential diagnosis between an onychomycosis and a psoriatic nail could be challenging; nevertheless, coexistence of onychomycosis and nail psoriasis also occurs and both are common disorders in the general population...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28917381/uncovering-burden-disparity-a-comparative-analysis-of-the-impact-of-moderate-to-severe-psoriasis-and-hidradenitis-suppurativa
#16
Iltefat H Hamzavi, Murali Sundaram, Cynthia Nicholson, Marko Zivkovic, Angela Parks-Miller, Jianyi Lee, Jingbo Yi, Yihua Gu, Martin M Okun, Arijit Ganguli, Steve R Arikian
BACKGROUND: Psoriasis and hidradenitis suppurativa (HS) exhibit distinct clinical features, but no studies have directly compared the health-related quality of life (HRQoL) in patients with moderate-to-severe manifestations of these conditions. OBJECTIVE: To determine which disease is associated with more severe HRQoL impairment. METHODS: Weighted averages of each of the following baseline HRQoL measures were determined and compared between HS and psoriasis populations from 5 clinical trials: Visual Analog Scale (VAS) for pain, Total Work Productivity Impairment, Dermatology Life Quality Index; EuroQOL 5D VAS, and Short Form-36 Health Survey...
September 13, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28906085/quality-of-life-of-psoriasis-patients-measured-by-the-psodisk-a-new-visual-method-for-assessing-the-impact-of-the-disease
#17
Santo R Mercuri, Greta Gregorio, Pina Brianti
BACKGROUND: Psoriasis is an inflammatory disease with a chronic course; often it is associated with various serious comorbidity and a compromised quality of life. Psoriasis patients experience a low self-esteem, feelings of shame and frustration, they report a seriously compromised social and sentimental sphere, difficulties at work and in daily activities, coming in most serious cases to suicidal ideation. METHODS: Our job is to experiment the introduction of the innovative PSOdisk tool to quantify the impact of psoriasis on quality of life, comparing it with PASI Index...
October 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/28898460/burden-of-chronic-urticaria-relative-to-psoriasis-in-five-european-countries
#18
M M Balp, S Khalil, H Tian, S Gabriel, J Vietri, T Zuberbier
BACKGROUND: Quantification of burden of chronic spontaneous urticaria (CSU) vs. psoriasis (PsO) is limited. OBJECTIVE: To evaluate the burden associated with CSU vs. PsO of all severities (overall PsO), mild and moderate/severe PsO. METHODS: This retrospective cross-sectional analysis compared data from adult patients with chronic urticaria (CU), used as a proxy for CSU, and PsO from the National Health and Wellness Survey in France, Germany, Italy, Spain and the United Kingdom...
September 12, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28887107/efficacy-of-systemic-treatments-of-psoriasis-on-pruritus-a-systemic-literature-review-and-meta-analysis
#19
Chloé Théréné, Emilie Brenaut, Thomas Barnetche, Laurent Misery
In the course of the last 30 years, several studies have clearly documented that pruritus is a very frequent symptom of psoriasis and its impact on the patients' quality of life. The variety of available systemic treatments for psoriasis is increasing rapidly. Our objective was to assess their efficacy on pruritus based on a systematic literature review. A systematic literature search was performed using PubMed and Trip Database (from January 1990 to September 2016) to find published clinical trials for the treatments of psoriasis, then a meta-analysis was performed...
September 5, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28881462/impact-of-ixekizumab-on-facial-psoriasis-and-related-quality-of-life-measures-in-moderate-to-severe-psoriasis-patients-12-week-results-from-2-phase-iii-trials
#20
C Paul, L Guenther, H Torii, H Sofen, R Burge, C Y Lin, A Potts Bleakman, L Mallbris, Y Poulin
BACKGROUND: Facial psoriasis was reported in 17-68% of patients with psoriasis and shown to have a negative impact on patients' personal and health-related quality of life (HRQoL). OBJECTIVES: Explore the association of facial psoriasis with patients' HRQoL and assess the relationship between ixekizumab (IXE) and improvement in facial psoriasis and changes in HRQoL. METHODS: This work reports the combined results of 2 phase III multicenter, randomized, double-blind, placebo-controlled, active-comparator trials in patients with moderate-to-severe psoriasis...
September 7, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
65639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"